Key Insights

Highlights

Treatment Research

8 treatments under study, led by Azacitidine

Research Leaders

5 sponsors active, led by Bristol-Myers Squibb

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Recruiting1
Active Not Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07018752Phase 1/2Recruiting

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

SYF62db398919f340ff8c8e08a7227b9f2bPhase 2Active Not Recruiting

Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas

Showing all 2 trials

Research Network

Common Treatments

  • Azacitidine1
  • Etoposide Teva 20 Mgml Concentrato Per Soluzione Per Infusione1
  • Venetoclax1
  • Golcadomide1
  • Selinexor1

Active Sponsors

  • Bristol-Myers Squibb1
  • Fondazione IRCCS Istituto Nazionale Dei Tumori1
  • AbbVie1
  • The Lymphoma Academic Research Organisation1
  • iOnctura1

Top Investigators

Related Conditions

  • Peripheral T Cells Lymphoma Ptcl1

Activity Timeline